
Finch Therapeutics brings on new CEO, CFO after January layoffs and scrapping a PhIII trial
Finch Therapeutics has had three rounds of layoffs in the past year and is now going through a leadership shakeup three months after scrapping a Phase III trial for one of its microbiome therapies.
Co-founder Mark Smith will step down as CEO and as a member of the board on May 15 for Matthew Blischak, who will take over as CEO on May 16. The company said in a statement that Smith is expected to stay on as a scientific and strategic advisor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.